maternal vaccination;
neonatal infections;
glycoconjugates;
women's health;
perinatal infections;
group B streptococci;
potency;
stability;
exclusion criteria;
D O I:
10.1016/S0264-410X(00)00437-0
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
The potency of clinical group B streptococcal (GBS) capsular polysaccharide-protein conjugate vaccines has been assessed with use of a mouse maternal vaccination-neonatal pup challenge model of GBS disease. Two of the three conjugated GBS vaccines bottled as liquid preparations showed a potency reduction from 100% to less than or equal to 50% in 3 years; whereas all six vaccines bottled as lyophilized preparations with sucrose excipient exhibited no loss of potency Juring the same span of time. A reconstituted GBS conjugate vaccine remained potent and antigenically intact after 31 days' storage at 2-8 degreesC. These data suggest that lyophilization in the presence of sucrose extends the potency of GBS conjugate vaccines. (C) 2001 Elsevier Science Ltd. All rights reserved.